A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study [PDF]
Clinical Infectious Diseases, 2018 Delafloxacin es una fluoroquinolona intravenosa (IV)/oral con actividad sobre los organismos anaeróbicos gram-positivos, gram-negativos, atípicos, incluyendo el Staphylococcus aureus resistente a methicillin.
Jaime Soria, Sue Cammarata
exaly +2 more sources
Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study [PDF]
Journal of Antimicrobial Chemotherapy, 2017 Funding Information: This work was funded by Melinta Therapeutics. In addition the editorial assistance (see below) was funded by Melinta Therapeutics.
Gardovskis, J., PROCEED Study Group
exaly +3 more sources
Related searches:
Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin
European Journal of Drug Metabolism and Pharmacokinetics, 2018Delafloxacin has recently received approval by the US Food and Drug Administration for the treatment of acute bacterial skin and skin structure infections. This article provides a balanced and comprehensive systematic critique of the literature in order to provide an up-to-date summary of its clinical pharmacology. Oral delafloxacin is rapidly absorbed
Jennifer, Shiu +2 more
openaire +2 more sources
Delafloxacin: An Improved Fluoroquinolone Developed through Advanced Molecular Engineering
Future Microbiology, 2018The emergence of antimicrobial resistance threatens current clinical practice across a range of infection types. Delafloxacin, a non-zwitterionic fluoroquinolone recently approved by the US FDA for the treatment of acute bacterial skin and skin structure infections, has been developed to address some of these challenges.
Bassetti M. +3 more
openaire +5 more sources
Susceptibility of Yersinia enterocolitica to the novel fluoroquinolone delafloxacin
Diagnostic Microbiology and Infectious Disease, 2020Minimum inhibitory concentration to delafloxacin and ciprofloxacin were performed with Y. enterocolitica, Y. frederiksenii and Y. kristensenii. All organisms were sensitive to delafloxacin and ciprofloxacin. Our study indicates that delafloxacin may have a reasonable in vitro susceptibility profile against Yersinia among the species studied, which has ...
Beverley C, Millar, John E, Moore
openaire +2 more sources
Efficacy of delafloxacin against the biothreat pathogenBacillus anthracis
Journal of Antimicrobial Chemotherapy, 2023AbstractObjectivesTo evaluate the in vitro activity and in vivo efficacy of delafloxacin against Bacillus anthracis, the causative agent of anthrax.MethodsMICs were obtained according to CLSI guidelines for 30 virulent isolates and 14 attenuated antibiotic-resistant strains.
Sandra McCurdy +9 more
openaire +2 more sources
Delafloxacin for the treatment of respiratory and skin infections
Expert Opinion on Investigational Drugs, 2015There has been a striking increase in the emergence of multidrug-resistant pathogens in recent times. Delafloxacin is a novel, broad-spectrum fluoroquinolone with antimicrobial activity against resistant Gram-positive, Gram-negative and anaerobic organisms.
BASSETTI, MATTEO +4 more
openaire +4 more sources
Delafloxacin as a treatment option for community-acquired pneumonia infection
Expert Opinion on Pharmacotherapy, 2021Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality in adults. Bacterial pathogens are recognized to be frequent causative agents, which makes antibacterial treatment crucial for the evolution of these patients. There are several antimicrobial options available in daily practice.
openaire +2 more sources
Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia
Expert Review of Anti-infective Therapy, 2021Delafloxacin is a novel fluoroquinolone with peculiar characteristics such as a weak acid character, frequent in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA), and a low potential for resistance selection compared with other fluoroquinolones.The present narrative review summarizes the available data on the use of ...
Bassetti, Matteo +2 more
openaire +2 more sources
What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2017Delafloxacin is a new fluoroquinolone antimicrobial approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults using dosage regimens of 300 mg intravenously every 12 hours, 450 mg orally every 12 hours, or switching from intravenous to oral regimens for a 5‐ to 14‐day treatment duration.
Cho, Jonathan C +3 more
openaire +3 more sources